nintedanib / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

9 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nintedanib / Generic mfg.
NCT03513484: Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

Active, not recruiting
1
44
US
Azacitidine, 5 AZC, 5-AC, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza, Laboratory Biomarker Analysis, Nintedanib, BIBF 1120, BIBF-1120, Intedanib, Multitargeted Tyrosine Kinase Inhibitor BIBF 1120, tyrosine kinase inhibitor BIBF 1120, Vargatef
Northwestern University, Robert H. Lurie Cancer Center, Boehringer Ingelheim, National Cancer Institute (NCI)
Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Fibroblast Growth Factor Basic Form Measurement, FLT3 Internal Tandem Duplication, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
12/25
01/27
NCT05830799: A Trial to Evaluate the Impact of C21 on the Exposure of 4 Substrates in Healthy Volunteers

Completed
1
18
Europe
Drug Drug Interaction, Caffeine, Koffein Meda, Tolbutamide, Tolbutamide CF, Midazolam, Midazolam APL, Nintedanib, Ofev
Vicore Pharma AB
Drug Interaction
05/23
05/23
NCT05817240: A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

Completed
1
21
RoW
taladegib, ENV-101, nintedanib
Endeavor Biomedicines, Inc.
Idiopathic Pulmonary Fibrosis
06/23
06/23
NCT05644600: A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.

Terminated
1
18
Europe
Nintedanib, AZD5055
AstraZeneca, Parexel
Healthy Subjects
07/23
07/23
NCT06070610: A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood

Completed
1
14
Europe
BI 1015550, Nintedanib, Ofev®, Pirfenidone, Esbriet®
Boehringer Ingelheim
Healthy
12/23
12/23
NCT02225405: Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

Completed
1
26
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Laboratory Biomarker Analysis, Nintedanib, BIBF 1120, BIBF-1120, Intedanib, Multitargeted Tyrosine Kinase Inhibitor BIBF 1120, tyrosine kinase inhibitor BIBF 1120, Vargatef
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
05/24
05/24
NCT06568458: A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Ninetedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

Not yet recruiting
1
73
NA
Nintedanib, BMS 986278
Bristol-Myers Squibb
Healthy Participants
11/24
11/24
NCT05195918: Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

Recruiting
1
50
US
EGCG 300 mg + Nintedanib, epigallocatechin-3-gallate + Ofev, EGCG 300 mg + Pirfenidone, epigallocatechin-3-gallate + Esbriet, Placebo 2 capsules + Nintedanib or Pirfenidone, Placebo + Ofev or Esbriet, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone
Hal Chapman, University of Michigan, Cornell University, Massachusetts General Hospital, Temple University, University of Washington
Idiopathic Pulmonary Fibrosis
03/25
03/25
PEMBIB, NCT02856425: Trial Of Pembrolizumab And Nintedanib

Recruiting
1
221
Europe
Nintedanib, Pembrolizumab
Gustave Roussy, Cancer Campus, Grand Paris
Patients With Any Advanced Solid Tumors
11/25
11/28

Download Options